CryoPort Sees Unusually Large Options Volume (NASDAQ:CYRX)

CryoPort, Inc. (NASDAQ:CYRX) was the recipient of unusually large options trading activity on Thursday. Stock traders bought 10,010 call options on the company. This is an increase of approximately 1,408% compared to the typical volume of 664 call options.

CryoPort Price Performance

CYRX stock traded down $0.12 during trading on Thursday, reaching $13.95. 103,404 shares of the company were exchanged, compared to its average volume of 463,536. The company has a market capitalization of $703.08 million, a price-to-earnings ratio of 10.33 and a beta of 1.75. The company has a 50-day moving average of $10.06 and a two-hundred day moving average of $9.58. CryoPort has a twelve month low of $5.31 and a twelve month high of $14.36.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The company had revenue of $47.80 million for the quarter, compared to analyst estimates of $44.86 million. On average, analysts forecast that CryoPort will post -0.74 EPS for the current year.

Insider Buying and Selling

In related news, CEO Jerrell Shelton sold 7,918 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $8.00, for a total value of $63,344.00. Following the completion of the sale, the chief executive officer owned 1,054,501 shares in the company, valued at approximately $8,436,008. This represents a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Mark W. Sawicki sold 3,235 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $8.00, for a total transaction of $25,880.00. Following the completion of the sale, the insider owned 103,697 shares in the company, valued at approximately $829,576. This trade represents a 3.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 59,939 shares of company stock valued at $471,183 over the last three months. Company insiders own 10.00% of the company’s stock.

Hedge Funds Weigh In On CryoPort

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS Group AG lifted its stake in shares of CryoPort by 6.8% in the fourth quarter. UBS Group AG now owns 1,421,884 shares of the company’s stock worth $13,650,000 after acquiring an additional 90,363 shares during the period. Mak Capital One LLC acquired a new position in shares of CryoPort during the third quarter valued at about $7,756,000. First Eagle Investment Management LLC bought a new position in CryoPort in the fourth quarter worth approximately $2,996,000. Segall Bryant & Hamill LLC bought a new position in shares of CryoPort in the 3rd quarter worth $652,000. Finally, Conestoga Capital Advisors LLC grew its holdings in shares of CryoPort by 52.0% during the fourth quarter. Conestoga Capital Advisors LLC now owns 159,864 shares of the company’s stock valued at $1,535,000 after buying an additional 54,675 shares during the last quarter. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CYRX has been the topic of several analyst reports. Needham & Company LLC boosted their price target on shares of CryoPort from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Wall Street Zen upgraded CryoPort from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Guggenheim boosted their price objective on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. BTIG Research raised their target price on CryoPort from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Finally, Weiss Ratings upgraded CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 6th. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $14.69.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.